{"id":164,"date":"2020-05-11T10:35:31","date_gmt":"2020-05-11T10:35:31","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=164"},"modified":"2020-05-11T10:35:31","modified_gmt":"2020-05-11T10:35:31","slug":"08-may-2020-remdesivir-faster-recovery-rates","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/08-may-2020-remdesivir-faster-recovery-rates\/","title":{"rendered":"(08 May 2020) Remdesivir- Faster recovery rates"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p>Efficacy of remdesivir in COVID-19 patients with a simulated two-arm controlled study<\/p>\n<p><a href=\"https:\/\/doi.org\/10.1101\/2020.05.02.20088559\">https:\/\/doi.org\/10.1101\/2020.05.02.20088559<\/a><\/p>\n<p>Findings from simulated two arm study suggests that Remdesivir treatment results in a 33% significantly higher odds of discharge, a 29% significantly lower risk of death, and a 39% significantly lower risk for the combined endpoint of severe status and death. The median time to discharge for the remdesivir treated group was around half of the median time-to-discharge compared with the control arm. Remdesivir is effective in treating COVID-19 patients in terms of enhancing recovery and accelerating discharge.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Efficacy of remdesivir in COVID-19 patients with a simulated two-arm controlled study https:\/\/doi.org\/10.1101\/2020.05.02.20088559 Findings from simulated two arm study suggests that Remdesivir treatment results in a 33% significantly higher odds of discharge, a 29% significantly lower risk of death, and&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/08-may-2020-remdesivir-faster-recovery-rates\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(08 May 2020) Remdesivir- Faster recovery rates&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,5],"tags":[25],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/164"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=164"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/164\/revisions"}],"predecessor-version":[{"id":165,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/164\/revisions\/165"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=164"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=164"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=164"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}